Announcements
Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Open Access
Review
Novel Therapies for Cardiometabolic Risk Reduction and Implications for Clinical Practice
Show Less
1
The David Geffen School of Medicine at the University of California, Los Angeles, UCLA Program in Preventive Cardiology, Los Angeles, CA
Rev. Cardiovasc. Med. 2007, 8(S4), 37–42;
Published: 20 August 2007
Abstract
The growing prevalence of obesity is associated with a dramatic increase in a number of related risk factors for cardiovascular disease and diabetes, including high triglyceride and fasting glucose levels, reduced high-density lipoprotein cholesterol, and increased blood pressure. For many patients, lifestyle interventions (eg, exercise and a reduced-calorie diet) are insufficient for overcoming obesity, and pharmacotherapy becomes necessary. Unfortunately, the currently available agents are associated with side effects such as gastrointestinal distress and increased blood pressure. A new class of drugs targeting the cannabinoid receptors is poised to join the obesity-management armamentarium, with one agent—rimonabant—demonstrating efficacy in 4 recent phase III multinational trials. Patients randomized to rimonabant 20 mg/d showed significant reductions in weight and significant improvements in lipid profiles and other measures of cardiometabolic risk factors.
Keywords
Cardiometabolic risk factors
Metabolic syndrome
Rimonabant
Obesity
Insulin sensitivity